• Company Type For Profit
  • Phone Number 81 3 6809 2199

REGiMMUNE Corporation is a private biopharmaceutical company developing innovative solutions for treating immune disorders caused by nonspecific and/or excessive immune reactions. REGiMMUNE uses its proprietary technology platform, reVax (reverse vaccination), to target immune tolerance against specific disease-causing antigens through

induction of regulatory T cells (Treg). This technology has potential applications in a number of immune system disorders and diseases including Graft versus Host Disease (GvHD), type 1 diabetes mellitus (T1DM), rheumatoid arthritis (RA), multiple sclerosis (MS) and systemic lupus erythematosus (SLE).

Currently, the company has one clinical-stage compound in a Phase I/II trial in the United States (RGI-2001) as a treatment for GvHD associated with hematopoietic stem cell transplantation and has a second product in preclinical development (RGI-3001) as a new treatment for T1DM. In addition, it has a number of well-differentiated compounds in its research-stage pipeline.

In healthy individuals, the normal immune system works to protect humans from disease-causing viruses, bacterium, and cancers; or foreign antigens such as peanuts, wheat and tree pollens. Conventional immunosuppressants have several significant side effects associated with long-term administration including risk of infection, toxicity and relapse. Products developed with ReVax technology are expected to reduce or eliminate such side effects as well as reduce long-term treatment.

Lists Featuring This Company

Asia-Pacific (APAC) Companies With Less Than $500M in Revenue (Top 10K)
9,965 Number of Organizations • $731.9B Total Funding Amount • 62,953 Number of Investors
Asia Companies With Less Than $1M in Revenue (Top 10K)
9,494 Number of Organizations • $50.6B Total Funding Amount • 11,099 Number of Investors
Asia Health Diagnostics Companies
2,684 Number of Organizations • $16.4B Total Funding Amount • 2,055 Number of Investors
Asia-Pacific (APAC) Biotechnology Companies
6,427 Number of Organizations • $98.3B Total Funding Amount • 9,896 Number of Investors

Frequently Asked Questions

Where is REGiMMUNE's headquarters? REGiMMUNE is located in Tokyo, Tokyo, Japan.Who invested in REGiMMUNE? REGiMMUNE has 29 investors including Mitsubishi UFJ Capital and Iyogin Capital.How much funding has REGiMMUNE raised to date? REGiMMUNE has raised .When was the last funding round for REGiMMUNE? REGiMMUNE closed its last funding round on May 10, 2017 from a Series E round.Who are REGiMMUNE's competitors? Alternatives and possible competitors to REGiMMUNE may include Krystal BiotechKSQ Therapeutics, and Innovent Biologics.